PVG Asset Management Corp acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,022 shares of the financial services provider’s stock, valued at approximately $415,000. iShares Biotechnology ETF comprises approximately 1.6% of PVG Asset Management Corp’s portfolio, making the stock its 17th biggest position.
Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Fin Capital Inc. increased its holdings in iShares Biotechnology ETF by 0.7% during the 2nd quarter. Blue Fin Capital Inc. now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after purchasing an additional 74 shares during the period. Security National Bank of SO Dak lifted its position in shares of iShares Biotechnology ETF by 0.7% in the 2nd quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock worth $1,436,000 after purchasing an additional 75 shares during the period. Main Street Financial Solutions LLC increased its holdings in iShares Biotechnology ETF by 1.0% during the second quarter. Main Street Financial Solutions LLC now owns 8,002 shares of the financial services provider’s stock valued at $1,098,000 after buying an additional 82 shares during the period. Perkins Coie Trust Co raised its stake in iShares Biotechnology ETF by 0.3% in the second quarter. Perkins Coie Trust Co now owns 25,184 shares of the financial services provider’s stock worth $3,457,000 after buying an additional 83 shares in the last quarter. Finally, HCR Wealth Advisors boosted its position in iShares Biotechnology ETF by 0.6% during the 2nd quarter. HCR Wealth Advisors now owns 13,453 shares of the financial services provider’s stock valued at $1,847,000 after acquiring an additional 83 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.
iShares Biotechnology ETF Price Performance
IBB opened at $145.60 on Tuesday. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $150.57. The stock has a fifty day moving average price of $145.69 and a 200-day moving average price of $138.91.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- Top Stocks Investing in 5G Technology
- DraftKings Is the Real MVP of the 2025 NFL Football Season
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.